Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase II Study of Paclitaxel Alone Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment of Patients With Metastatic Breast Cancer

NCT01320111 is registered in ClinicalTrials.gov with Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH as lead sponsor.

NCT NCT01320111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01320111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase II Study of Paclitaxel Alone Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment of Patients With Metastatic Breast Cancer
Lead sponsor
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2010
Completion date
August 31, 2014
Enrollment
59 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer